Affiliation:
1. Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
2. Affinium Pharmaceuticals, Inc., Toronto, Ontario, Canada
Abstract
ABSTRACT
AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of
Staphylococcus aureus
(
n
= 502) and
Staphylococcus epidermidis
(
n
= 51) tested, including methicillin (meticillin)-resistant isolates, at concentrations of ≤0.12 μg/ml. In contrast, AFN-1252 was inactive (MIC
90
, >4 μg/ml) against clinical isolates of
Streptococcus pneumoniae
, beta-hemolytic streptococci,
Enterococcus
spp.,
Enterobacteriaceae
, nonfermentative gram-negative bacilli, and
Moraxella catarrhalis
. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference12 articles.
1. Bacterial Fatty Acid Biosynthesis: Targets for Antibacterial Drug Discovery
2. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement 2007 vol. 27
3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2006
4. Reference deleted.
5. Reference deleted.
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献